HepaRegeniX, a biotech company founded in 2016, specialises in developing drugs that restore the regenerative capacity of diseased livers. The three founders of the biotech start-up, Prof. Dr. Lars Zender, Prof. Dr. Stefan Laufer and Dr. Wolfgang Albrecht, anticipate starting clinical testing of the first drug candidate in 2019.
Malaria, which is a mosquito-borne disease caused by Plasmodium parasites, is still one of the worst infectious human diseases. The parasites have developed resistance against previously effective drugs and new strategies to combat malaria are urgently needed.
Butyric acid is an important source of fruity aromas. It accumulates as an intermediary product during biogas production, from where it can be siphoned off and used for producing flavours. A new collaborative project aims to explore the technological and bioeconomic potential of extracting butyric acid from biogas plants.
The Freiburg-based start-up company Ö-Klo leases composting toilets and is committed to the recovery of human urine and faeces. The young Ö-Klo entrepreneurs believe that reviving natural material cycles of soil, plants, food and excreta is crucial in times when natural resources such as phosphorus are dwindling.